hotspot -WSS

hotspot

author：leisure time 2025-09-27 06:09:37 - browse：6

Person wearing a blue glove holding money against a blue backdrop. — Adobe

Covid vaccines saved nearly 20 million lives worldwide, by one estimate, and generated billions of dollars for several drugmakers. But investment in experimental vaccines for dozens of other diseases remains modest and should be much higher, according to a new biotechnology industry report.

Even with the historic effort to develop coronavirus vaccines, including shots created by Cambridge, Mass.-based Moderna, drugmakers developing new vaccines for infectious diseases received 3.4% of all venture capital raised for biopharma companies in the past 10 years, for a total of $6.5 billion, the report said.

In comparison, firms with potential cancer drugs received 38% of venture capital, or $72.6 billion — 12 times as much — during the same period, according to the report by the Biotechnology Innovation Organization, or BIO, the world’s largest biotech trade group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Snackable artificial intelligence, expert AI, and the pharma industry

hotspot

WSS

How to fix cancer clinical trials' diversity problem

Advances in CAR

What drug price negotiations mean for Medicare Part D

Weighted lottery helped low

The 10 drugs up first for Medicare price negotiation

ALS advocates say criticism of new drugs misses bigger picture

focus

hotspot

entertainment

Continuity nursing helped my family in our darkest PICU moments

Illumina names Agilent executive as new CEO

Anesthesiologist group: stop taking Ozempic before surgery

Stem cell treatment guidelines are released by FDA

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Advances in CAR

Duchenne breakthrough therapy leaves behind pioneering families

Amazon on where the company's health care bets are headed next

Novavax promises a turnaround & Lilly roils the obesity market

Advances in CAR

focus

Why Novartis is changing the name of its research labs

The 10 drugs up first for Medicare price negotiation

What drug price negotiations mean for Medicare Part D

The (many) problems with a new study criticizing cancer screening

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Covid hospitalizations on the rise, Humana says

hotspot

focus

hotspot

explore